&nbsp;

Jan 2018

Drug

oBINutuzumab

Other Name(s): Gazyva®

Quick Link(s):

May 2022

Regimen

ERIB

Cancer Type:

Breast

Intent: Palliative

Funding:

New Drug Funding Program

Eribulin - Metastatic or Incurable Locally Advanced - Breast Cancer

Drugs Used:

eriBULin

Quick Link(s):

Regimen Monograph

Jan 2018

Regimen

OXALRALT

Cancer Type:

Gastrointestinal,

Colorectal,

Esophagus,

Gastric / Stomach,

Small bowel and appendix

Intent: Adjuvant, Palliative

Funding:

New Drug Funding Program

Raltitrexed - Metastatic Colorectal Small Bowel or Appendiceal Cancer

New Drug Funding Program

Raltitrexed - Metastatic Esophageal, Gastroesophageal Junction, or Gastric Cancer

New Drug Funding Program

Raltitrexed - Adjuvant Colorectal, Small Bowel, or Appendiceal Cancer

New Drug Funding Program

Raltitrexed - Adjuvant Esophageal, Gastroesophageal Junction, or Gastric Cancer

Drugs Used:

raltitrexed,

oxaliplatin

Quick Link(s):

Regimen Monograph

Apr 2023

Regimen

EPOCH+RITU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade,

Lymphoma - Non-Hodgkin's Intermediate Grade

Intent: Curative

Funding:

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Aggressive Histology Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - HIV-Related Aggressive Histology B-cell Lymphoma

ODB - General Benefit

prednisone

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Aggressive Histology Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - HIV-Related Aggressive Histology B-cell Lymphoma

Drugs Used:

Quick Link(s):

Regimen Monograph

Aug 2020

Regimen

OBIN(MNT)

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

New Drug Funding Program

Obinutuzumab - Maintenance Treatment for Refractory Follicular Lymphoma

Drugs Used:

oBINutuzumab

Quick Link(s):

Regimen Monograph

Dec 2019

Drug

Erwinia asparaginase

Other Name(s): Erwinase®

Quick Link(s):

Drug Monograph

Jan 2020

Regimen

ENFO

Cancer Type:

Genitourinary,

Bladder / Urothelial

Intent: Palliative

Funding:

New Drug Funding Program

Enfortumab Vedotin - Previously Treated Advanced or Metastatic Urothelial Cancer

Drugs Used:

enfortumab vedotin

Quick Link(s):

Regimen Monograph

Jan 2025

Drug

enfortumab vedotin

Other Name(s): Padcev®

Quick Link(s):

Aug 2025

Drug

Enhertu trastuzumab deruxtecan

Other Name(s): Enhertu®

Quick Link(s):

May 2025

Regimen

EPCO; EPCO(RAMP)

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade,

Lymphoma - Non-Hodgkin's Intermediate Grade

Intent: Palliative

Funding:

New Drug Funding Program

Epcoritamab (Outpatient) - Relapsed or Refractory Diffuse Large B-Cell Lymphoma

High Cost Therapy Funding Program

Epcoritamab (Inpatient) - Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Drugs Used:

epcoritamab

Quick Link(s):

Regimen Monograph

Aug 2025

Drug

epcoritamab

Other Name(s): Epkinly™

Quick Link(s):